

Mr. GORDON. Concerning novobiocin, is it correct that the panels of the NAS-NRC recommended that it be taken off the market?

Dr. EICHENWALD. In the case of novobiocin, if I remember correctly, there was a split vote. A majority of the panel felt it should be removed. A minority felt that it should be permitted to remain on the market with a very stringent warning note. This is information that was transmitted to the FDA.

Senator NELSON. I want to thank both of you for your very valuable contribution to these hearings, and again repeat, we appreciate your taking the time from your very busy schedules to come here today.

Thank you very much.

We will resume hearings at 9 o'clock tomorrow morning.

(Whereupon, at 11:35 a.m., the hearing was recessed, to reconvene at 9 a.m., Wednesday, May 7, 1969.)